Correlation Between Eyenovia and Virpax Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Eyenovia and Virpax Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Eyenovia and Virpax Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Eyenovia and Virpax Pharmaceuticals, you can compare the effects of market volatilities on Eyenovia and Virpax Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Eyenovia with a short position of Virpax Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Eyenovia and Virpax Pharmaceuticals.

Diversification Opportunities for Eyenovia and Virpax Pharmaceuticals

0.7

Correlation Coefficient

Eyenovia  Virpax Pharmaceuticals

Poor diversification

The 3 months correlation between Eyenovia and Virpax is 0.7. Overlapping area represents the amount of risk that can be diversified away by holding Eyenovia and Virpax Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Virpax Pharmaceuticals and Eyenovia is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Eyenovia are associated (or correlated) with Virpax Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Virpax Pharmaceuticals has no effect on the direction of Eyenovia i.e., Eyenovia and Virpax Pharmaceuticals go up and down completely randomly.

Pair Corralation between Eyenovia and Virpax Pharmaceuticals

Given the investment horizon of 90 days Eyenovia is expected to under-perform the Virpax Pharmaceuticals. In addition to that, Eyenovia is 1.89 times more volatile than Virpax Pharmaceuticals. It trades about -0.18 of its total potential returns per unit of risk. Virpax Pharmaceuticals is currently generating about -0.18 per unit of volatility. If you would invest  65.00  in Virpax Pharmaceuticals on September 15, 2024 and sell it today you would lose (25.00) from holding Virpax Pharmaceuticals or give up 38.46% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Eyenovia  vs.  Virpax Pharmaceuticals

Eyenovia

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Eyenovia has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Virpax Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Virpax Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Eyenovia and Virpax Pharmaceuticals

The main advantage of trading using opposite Eyenovia and Virpax Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Eyenovia position performs unexpectedly, Virpax Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Virpax Pharmaceuticals will offset losses from the drop in Virpax Pharmaceuticals' long position.

The idea behind Eyenovia and Virpax Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.